Arndt Vogel, managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, shared a post on X:
“Trastuzumab deruxtecan in HER2+ gastric cancer
exploratory biomarker analysis of DESTINY Gastric01
64% concordance btw HER2+ IHC and blood
MET, EGFR and FGFR2 GA: ORR low
HER2 mutations: ORR high
activity in Her2 low.”
Read further.
Source: Arndt Vogel/X